Related Experiment Video
Updated: Jun 5, 2025

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
Published on: May 1, 2020
The GATA-3-dependent transcriptome and tumor microenvironment are regulated by eIF4E and XPO1 in T-cell lymphomas
Nermin Kady1,2, Suhaib Abdelrahman1, Ahmar M Rauf1
1Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.
Abstract:
The transcription factor GATA-binding protein 3 (GATA-3) and the transcriptional program it regulates have emerged as oncogenic drivers across diverse T-cell lymphomas (TCLs), many of which are resistant to conventional chemotherapeutic agents and characterized by recurrent losses of key tumor suppressor genes, including TP53 and PTEN, both of which are clients of the nuclear export protein XPO1. Here, we demonstrated that XPO1 is highly expressed by malignant T cells expressing GATA-3 and by lymphoma-associated macrophages (LAMs) within their tumor microenvironment (TME). Using complementary genetically engineered mouse models, we demonstrated that TP53- and/or phosphate and tensin homolog (PTEN)-deficient TCLs, and LAMs within their TME, are sensitive to the selective exportin-1 (XPO1) antagonist selinexor. In an effort to identify TP53- and PTEN-independent mechanisms, we used complementary and orthogonal approaches to investigate the role of eIF4E and XPO1-dependent messenger RNA nuclear export in these TCLs. We identified a novel role for eIF4E/XPO1 in exporting GATA-3 and GATA-3-dependent transcripts from the nucleus in TCLs, and in the export of therapeutically relevant transcripts, including colony-stimulating factor-1 receptor, from LAMs. Therefore, XPO1 antagonism, by impairing oncogenic transcriptional programs in TCLs and depleting LAMs from their TME, is a novel approach to target 2 independent dependencies in a group of therapeutically challenging TCLs.
Insights
The nuclear export protein XPO1 is highly expressed in T-cell lymphomas (TCLs) and their microenvironment. Targeting XPO1 with selinexor shows promise for treating these challenging cancers.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- GATA-binding protein 3 (GATA-3) drives oncogenesis in T-cell lymphomas (TCLs).
- Many TCLs are chemoresistant and lose tumor suppressors like TP53 and PTEN, which are linked to nuclear export protein XPO1.
- XPO1 is upregulated in malignant T cells and lymphoma-associated macrophages (LAMs) within the tumor microenvironment (TME).
Purpose of the Study:
- To investigate the role of XPO1 in TCLs, particularly in TP53- and PTEN-deficient contexts.
- To explore TP53- and PTEN-independent mechanisms involving eIF4E and XPO1 in TCLs.
- To evaluate selinexor, a selective XPO1 antagonist, as a therapeutic agent for TCLs.
Main Methods:
- Utilized genetically engineered mouse models of TCLs.
- Employed complementary and orthogonal approaches to study eIF4E and XPO1 in TCLs.
- Assessed the expression of XPO1 in malignant T cells and LAMs within the TME.
Main Results:
- TP53- and/or PTEN-deficient TCLs and their associated LAMs are sensitive to selinexor.
- Identified a novel role for eIF4E/XPO1 in the nuclear export of GATA-3 and its dependent transcripts in TCLs.
- Demonstrated XPO1's role in exporting therapeutically relevant transcripts, such as colony-stimulating factor-1 receptor, from LAMs.
Conclusions:
- XPO1 antagonism impairs oncogenic transcriptional programs in TCLs.
- XPO1 antagonism depletes LAMs from the TME.
- Targeting XPO1 offers a novel strategy to address two independent dependencies in difficult-to-treat TCLs.
More Related Videos
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Master Transcription Regulators
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
Regulation of Angiogenesis and Blood Supply
General Transcription Factors

